Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements.
Pharma is one of the few sectors where mature franchises, regulatory moats, and predictable free cash flow fund decades of uninterrupted payouts. Patent cliffs and pricing pressure compress multiples, which is why several big-cap drugmakers now trade with yields well above the S&P 500 average. That setup gives income investors same-day liquidity, no leverage, and a payout backed by global drug demand.
We screened our 24/7 Wall St. dividend equity research database and found six companies that, combined, can generate over $850 a year in passive annual income on a $25,000 investment ($4,166.67 per stock).
AstraZeneca
- Yield: 1.71%
- Shares for $4,166.67: 22
- Annual Passive Income: $71
AstraZeneca (NASDAQ:AZN | AZN Price Prediction) is a UK-domiciled global drugmaker with leadership in oncology, rare disease, and biopharmaceuticals. Q1 2026 revenue grew 13% to $15.29B, with oncology up 20% on Tagrisso, Imfinzi, and Enhertu. Management intends to lift the FY26 dividend to $3.30 per share, a meaningful step up from $1.565 paid in 2025. Institutions hold roughly 64.5% of the float.
Johnson & Johnson
- Yield: 2.26%
- Shares for $4,166.67: 18
- Annual Passive Income: $94
Johnson & Johnson (NYSE:JNJ) is a Dividend King with 64 consecutive years of increases, most recently a 3.1% raise to $1.34 per quarter payable June 9, 2026. Innovative Medicine grew 11.2% in Q1 led by DARZALEX and TREMFYA, offsetting STELARA biosimilar erosion. The yield sits at the bottom of the group because the market pays up for AAA-rated balance-sheet quality and a planned Orthopaedics separation.
Merck
- Yield: 3%
- Shares for $4,166.67: 36
- Annual Passive Income: $125
Merck (NYSE:MRK) anchors the portfolio with KEYTRUDA, which generated $8.03B in Q1 (up 12%), alongside fast-growing WINREVAIR and a recovering Animal Health segment. The quarterly payout was raised to $0.85, an annualized $3.40. Shares were pressured by the $9B Cidara acquisition charge and GARDASIL weakness in China. With institutional ownership at 81.3% and a forward P/E near 22, the dividend is funded by KEYTRUDA cash flow with years of exclusivity remaining.
AbbVie
- Yield: 3.19%
- Shares for $4,166.67: 20
- Annual Passive Income: $133
AbbVie (NYSE:ABBV) inherited Abbott’s aristocrat lineage and now pays $1.73 per quarter, an annualized $6.92. Skyrizi and Rinvoq are absorbing the Humira cliff: Q1 2026 revenue rose 12.4% to $15B, and management raised FY26 adjusted EPS guidance to $14.08 to $14.28. Capital is flowing into US capacity, including a $1.4B Durham campus.
Bristol Myers Squibb
- Yield: 4.11%
- Shares for $4,166.67: 72
- Annual Passive Income: $171
Bristol Myers Squibb (NYSE:BMY) trades at one of the lowest forward multiples in big pharma, around 9, which is why the yield is rich. The Growth Portfolio expanded 12% to $6.23B in Q1 on Eliquis, Camzyos, and Breyanzi, while legacy Revlimid generics drag. The quarterly dividend was raised to $0.63, and roughly $5B remains under buyback authorization. Institutions own 83.4% of shares, supporting a payout ratio of 69.75%.
Pfizer
- Yield: 6.44%
- Shares for $4,166.67: 158
- Annual Passive Income: $268
Pfizer (NYSE:PFE) carries the highest yield, paying $0.43 per quarter for an annualized $1.72. The headline yield reflects post-COVID revenue normalization (Comirnaty -33%, Paxlovid -70%) offset by a non-COVID portfolio growing 9% operationally. The trailing payout ratio of 126.47% is the watch item, but FY26 guidance of $2.80 to $3 in adjusted EPS recovers coverage. Institutions hold 67.9%, and the $7B Metsera obesity deal opens a fresh growth lane.
| Ticker | Investment | Yield | Annual Income |
|---|---|---|---|
| PFE | $4,166.67 | 6.44% | $268 |
| BMY | $4,166.67 | 4.11% | $171 |
| ABBV | $4,166.67 | 3.19% | $133 |
| MRK | $4,166.67 | 3.00% | $125 |
| JNJ | $4,166.67 | 2.26% | $94 |
| AZN | $4,166.67 | 1.71% | $71 |
Combined, these six positions generate roughly $863 in annual passive income on a $25,000 investment, a blended yield of 3.45%. Reinvested at the same blended yield, that income compounds while underlying franchises develop the next decade of pipeline assets. Pharma payouts arrive from balance sheets that survive recessions, regulatory shocks, and patent cliffs. For an income portfolio that needs to keep paying through every market cycle, that durability matters.
Top Gaining Stocks
Top Losing Stocks